Use of Cardiac Safety Data in Early Phase Trials to Supplement or Replace a Thorough QT Trial
We respect your privacy, by clicking ‘Watch On-Demand’ you agree to having your details passed onto the sponsors who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.
Cardiac safety assessment, and particularly the evaluation of a drug’s effect on QTc, are required for all new chemical entities. This webinar will discuss strategies for collecting cardiac safety data in early phases in order to complement or help with the design of a definitive QT trial, as well as the circumstances in which early phase QT assessment may be able to replace a standard Thorough QT Trial.
Key learning points: The webinar will address:
- How early phase ECG data can help de-risk a compound
- How early phase ECG data may help with the planning of a TQT
- How early phase ECG data may replace a TQT under certain circumstances
- Best practices for ECG collection in early phase trials
*Participants limited at our discretion.
Presenters:
Robert Kleiman M.D.
Chief Medical Officer & Vice President, Global Cardiology
ERT
We respect your privacy, by clicking ‘Watch On-Demand’ you agree to having your details passed onto the sponsors who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.
